Orthotopic liver transplantation in U.S. veterans under primary tacrolimus immunosupression
Gayowski, T.; Marino, I.R.; Singh, N.; Doyle, H.R.; Wagener, M.M.; Todo, S.; Fung, J.J.; Starzl, T.E.
Surgical Technology International 5: 223-232
1996
ISSN/ISBN: 1090-3941 PMID: 15858745 Document Number: 454919
The evolution and refinement of surgical techniques, per ioperative patient care, and immunosuppression hav~ estab~ished orthoto~ic li~er transplantation (OLTX) as a ~ighly successful therapeutic modality for patients wrth end-stage hver disease. In February 1989,Tacrohmus (Prograf®, formerly FK 506)was first used successfully at the University of Pittsburgh Medical Center to treat patients with rejection refractory to cyclosporine-based immunosuppression." Clinical trials utilizing Tacrolimus in solid organ transplantation followed, and in April of 1994 it was approved for use by the Food and Drug Administration,